Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027497 (nausea)
 23,468 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A 48-year-old Thai female, who had stage 2 carcinoma of the breast presented with recalcitrant erythrodermic psoriasis which was unresponsive to conventional therapies. She was prescribed 6 mg/kg.day cyclosporin A. The erythroderma responded rapidly and was completely cleared within 3 weeks. The dosage was reduced in a step-wise manner to 4 and then 2 mg/kg.day and was stopped after 2 months of treatment. Complete clearing of the skin lesion was observed without any side-effects except mild nausea. The patient was then referred to surgery for mastectomy and chemotherapy. There was no clinical relapse during more than 1 year of follow-up and at present she is continuing to do well.
 ...
PMID:The use of low dose cyclosporin A in a case of recalcitrant erythrodermic psoriasis. 323 97

In a previous study we evaluated a microcrystalline preparation of 5-methoxypsoralen (5-MOP; Bergapten) for its photochemotherapeutic properties. Preliminary data indicated that the clinical efficacy of 5-MOP is comparable to that of 8-methoxypsoralen. 5-MOP appeared as a promising alternative photosensitizer for the management of psoriasis because of the almost complete lack of phototoxic and drug intolerance reactions that are frequently encountered in patients undergoing 8-MOP photochemotherapy. With a new liquid preparation of 5-MOP we have now extended our earlier investigation on a larger clinical scale and have correlated the clinical response with the bioavailability of the drug. Serum level determinations showed an absorption rate of only approximately 25% that of 8-MOP. When administered in the same dosage as 8-MOP, 5-MOP turned out to be significantly less effective; however, by doubling the oral dosage, comparable results in terms of clearing of psoriasis were obtained. Also with this high-dose 5-MOP regimen, no drug intolerance was noted and other side effects, such as severe erythema, pruritus, and nausea, occurred only rarely. We propose 5-MOP as a valuable alternative for photochemotherapy (PUVA) of PUVA-responsive diseases.
 ...
PMID:5-Methoxypsoralen (Bergapten) for photochemotherapy. Bioavailability, phototoxicity, and clinical efficacy in psoriasis of a new drug preparation. 327 89

A questionnaire survey of British tanning salon clients disclosed that immediate side effects occurred more frequently in women using oral contraceptives. 20 questionnaires distributed to each of 146 UV-A lamp tanning salons nationwide in 1985 covered 24 questions on topics such as age, sex and skin type of the respondents, skin conditions such as acne and psoriasis, satisfaction with tan, and side effects including erythema (redness), itching, rash and nausea. Half of the subjects were young women aged 15-30, who had used the sunbed 10 to 100 times (median 20 times). Most sessions lasted 30 minutes. 98% reported that they tanned; 83% claimed they felt more relaxed; 28% complained of itching; 8% had rash or nausea. Among those with side effects, 41% with itching took oral contraceptives, compared to 27% who did not (p.005). 17% of pill users had nausea and 14% got a rash, compared to 10 and 7% of non-pill users, respectively (p.025). 195 or 19% of the 1013 respondents were on the pill. There are several conditions known to predispose to skin reddening, irritation or possibly carcinogenesis: fair skin; idiopathic light sensitivity; use of certain cosmetics or drugs such as antibiotics, antihypertension drugs, or antipsychotic agents.
 ...
PMID:Use of UV-A sunbeds for cosmetic tanning. 373 Feb 79

Sixty patients suffering from psoriasis of all clinical forms have been treated with an increased dosage of Bromocriptin. The age of the patients ranged from 20 to 72 years. Patients with contraindications for Bromocriptin were excluded from the test. In 80% a remission or reduction of psoriasis lesions was noticed. Side effects in the form of nausea, dizziness and vomiting occurred in 15%, but decreased in the course of Bromocriptin therapy.
 ...
PMID:Treatment of psoriasis with bromocriptin. 612 Jun 82

Thirty-six psoriatic patients resistant to or intolerant to PUVA, methotrexate and/or etretinate were treated with razoxane (ICRF 159) and EDTA derivative with antimitotic effects. The drug is highly effective in cutaneous and arthropathic psoriasis. Razoxane is well tolerated and appears to be free of hepatotoxicity. Besides some nausea and lethargy, 60% of the patients showed neutropenia, which can be easily controlled.
 ...
PMID:Razoxane in the treatment of psoriatic patients resistant to or intolerant of PUVA, methotrexate and etretinate. 618 78

The effectiveness of methoxsalen and ultraviolet light (PUVA) in treating is reviewed. The use of this therapy, its mechanism of action, pharmacology, pharmacokinetics, adverse reactions, dosage, and comparison with other forms of therapy, are discussed. Administered orally, methoxsalen in combination with long-range ultraviolet light (UVA) is effective in treating patients with moderate to severe forms of psoriasis. Although the short-term risks associated with PUVA therapy are minimal, the long-term risks of oncogenicity have not been evaluated thoroughly. Common adverse reactions to methoxsalen and UVA are nausea, pruritus, and erythema, but usually they can be managed by minor modifications in the treatment regimen. Methoxsalen and UVA therapy should be reserved for patients with moderate to severe forms of psoriasis that do not respond to other forms of therapy until the long-term risks of oncogenicity are evaluated.
 ...
PMID:Photochemotherapy of psoriasis with methoxsalen and longwave ultraviolet light (PUVA). 702 Apr 14

The effect of oral doses of colchicine on pustule formation was studied in 32 patients with pustulosis palmaris et plantaris without associated psoriasis. Oral administration of colchicine, 1 to 2 mg daily, was started during periods of disease exacerbation, and the dosage was gradually decreased to 0.5 to 1 mg daily in responsive patients. Thirteen patients showed complete clearing of pustulation, and 14 patients showed a remarkable reduction in pustule formation after two to eight weeks of treatment. One patient did not respond and four discontinued treatment because of nausea or diarrhea. During a three-month follow-up evaluation after treatment was stopped, relapse occurred in eight cases. Colchicine appears to be effective in the suppression of acute exacerbations of pustulosis palmaris et plantaris.
 ...
PMID:Treatment of pustulosis palmaris et plantaris with oral doses of colchicine. 709 69

Thirty-eight patients with plaque-type psoriasis were enrolled in a double-blind psoralen plus ultraviolet A (PUVA) treatment study comparing the efficacy and side effects of 5-methoxypsoralen (5-MOP) and 8-methoxypsoralen (8-MOP). Patients treated with 8-MOP healed significantly faster than those on 5-MOP for 6 weeks of treatment, but there was no significant difference after 9 weeks. There was no significant difference in side effects between the two groups, but nausea tended to be more common in the 8-MOP group. One patient on 5-MOP had signs of toxic hepatitis. The importance for maximizing absorption of taking 5-MOP with food is stressed, and PUVA treatment should be given 3 h after intake of the drug.
 ...
PMID:Treatment of psoriasis with psoralens and ultraviolet A. A double-blind comparison of 8-methoxypsoralen and 5-methoxypsoralen. 788 Jul 62

Possible new indications for the use of octreotide are discussed. In October 1988, octreotide received FDA-approved labeling for use in the management of carcinoid syndrome and vipomas. Since that time, research results and clinical experience have accumulated that suggest a potentially much broader therapeutic role for octreotide. Reports continue to be published on the use of octreotide for treating pituitary tumors, gastroenteropancreatic tumors, diabetes mellitus, AIDS-associated diarrhea, autonomic neuropathy, pancreatitis, pancreatic pseudocysts and ascites, complications of pancreatic surgery and transplantation, ileostomy-associated diarrhea, enterocutaneous fistulas, pancreatic fistulas, dumping syndrome, short bowel syndrome, and gastrointestinal bleeding. Other emerging indications for the use of octreotide include psoriasis, hypercalcemia, cancer-related pain, polycystic ovary syndrome, and certain cancers. In children, octreotide has been studied for use in treating hyperinsulinemic hypoglycemia of infancy. Along with the common adverse effects of octreotide, such as pain at the injection site and nausea, less frequent effects, such as cholelithiasis, gallbladder hypercontractility, and gastritis have now been described. Much of what has been learned is based on small uncontrolled studies and case reports, since the rarity of many of the conditions for which octreotide has shown promise has tended to preclude larger studies. As clinical experience with octreotide accumulates and better-designed trials are completed where possible, a broader therapeutic role for octreotide is likely to be recognized.
 ...
PMID:Emerging indications for octreotide therapy, Part 1. 804 37

In the past 22 years, 113 patients with severe psoriasis have been treated with low-dose methotrexate (MTX) in our department. The maximum weekly dosage was 15 mg (Weinstein schedule), the estimated mean cumulative dose was 4803 mg, and the estimated mean duration of therapy was 8 years and 11 months. In 81% of the patients, prolonged clearance or near clearance was achieved, indicating the potent and sustained potential of MTX in the treatment of both the pustular and erythematosquamous variants of psoriasis. Eighty-three patients (73%) had side-effects, most frequently abnormal liver function tests, nausea and gastric complaints. Apart from hair loss in seven patients, there were no mucocutaneous side-effects, probably because of the low-dose treatment schedule. In 71 patients MTX therapy was discontinued; in 33 patients because of side-effects. In 55 patients one or more liver biopsies were performed. Fibrosis was seen in seven of these patients (13%) and cirrhosis in two (4%). There was no relation between liver biopsy classification and cumulative dosage or duration of MTX therapy, nor was there any relation between liver histology and abnormal liver function tests. During this 22-year period, there were no deaths or life-threatening side-effects attributable to MTX treatment. We conclude that low-dose MTX (< or = 15 mg/week) is a relatively safe therapy for severe psoriasis, if patients are carefully selected beforehand, and regular monitoring for side-effects and drug interactions is performed during therapy.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Methotrexate revisited: effects of long-term treatment in psoriasis. 812 73


<< Previous 1 2 3 4 5 6 7 8 9 Next >>